Nightmares Associated to Nevirapine during Chemoradiotherapy for Carcinoma Tongue
Bhooshan Zade
Department of Radiation Oncology, Indrayani Hospital, Pune, India.
Vrushab Rao
*
Department of Radiation Oncology, Ruby Hall Clinic, Pune, India.
*Author to whom correspondence should be addressed.
Abstract
Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a drug used in the management and treatment of HIV. It is considered safe for use in conjunction with platinum-based chemotherapy. Chemotherapy is a staple of cancer treatment and is used routinely in the management of malignancies of the head and neck. However, managing HIV-positive cancers presents challenges due to individual side effects and drug interactions. Drug interactions can potentiate or reduce drug metabolism, reduce excretion, or cause adverse drug reactions.
Herein, we describe a case of new-onset nevirapine-induced nightmares that was noted in a patient undergoing chemoradiotherapy with cisplatin.
Keywords: Case report, nevirapine, radiotherapy, chemotherapy, cisplatin, toxicity, adverse drug reactions